Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.
Aranzazu Fernández-Martínez(University of North Carolina at Chapel Hill), Charles M. Perou(University of North Carolina at Chapel Hill), Ian E. Krop(Yale Cancer Center), Ann H. Partridge(Dana-Farber Cancer Institute), Tomás Pascual(Breast Cancer Research Foundation), Maki Tanioka(University of North Carolina at Chapel Hill), Javier Cortés(Villa Maria Hospital), Lisa A. Carey(University of North Carolina at Chapel Hill), Joel S. Parker(University of North Carolina at Chapel Hill), Patricia Galván(Vall d'Hebron Institute of Oncology), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Aleix Prat(Hospital Clínic de Barcelona), Katherine A. Hoadley(University of North Carolina at Chapel Hill), Cheng Fan(University of North Carolina at Chapel Hill), Antonio Llombart‐Cussac(MedSIR (Spain))
Cited by 7
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k